Cougar's prostate cancer hope abiraterone shows early promise
This article was originally published in Scrip
Cougar Biotechnology's lead compound, a novel hormonal treatment for prostate cancer, has shown benefit in a Phase I study published in the Journal of Clinical Oncology.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.